<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04470336</url>
  </required_header>
  <id_info>
    <org_study_id>JHB/190702/NATIVECTII/OA</org_study_id>
    <nct_id>NCT04470336</nct_id>
  </id_info>
  <brief_title>To Assess the Efficacy of Native CT-II® in Osteoarthritis</brief_title>
  <official_title>A Double-blind, Placebo-controlled, Randomized, Parallel Study to Assess the Efficacy of Native CT-II® in Osteoarthritis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Vedic Lifesciences Pvt. Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Vedic Lifesciences Pvt. Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Native CT-II® is a natural ingredient that contains undenatured type-II collagen derived from
      chicken sternum. Undenatured type II collagen in Native CT-II® is efficacious and safe as
      compared to placebo and efficacy is also comparable to glucosamine plus chondroitin for
      treatment of of knee Osteoarthritis
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 9, 2020</start_date>
  <completion_date type="Anticipated">March 10, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 10, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>modified Western Ontario and McMaster Score</measure>
    <time_frame>Day0 Day 28 Day 56 Day 84</time_frame>
    <description>Effect of consumption of IP on Joint health as assessed by the change in the (mWOMAC) total score from baseline and when compared with the placebo. [From baseline to 84 days] High score defines worst outcome and low score defines better oucome.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>EQ-5D-5L</measure>
    <time_frame>Day 0 and Day 84</time_frame>
    <description>Effect of consumption of IP on Joint health as assessed by the change in the EQ-5D-5L from baseline and when compared with the placebo. [From baseline to 84 days]</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>interleukin-6 (IL - 6)</measure>
    <time_frame>Day 0 Day 84</time_frame>
    <description>Effect of consumption of IP on Joint inflammation as assessed by the change in the inflammatory biomarker interleukin-6 (IL-6) concentration from baseline and when compared with the placebo. [From baseline to 84 days]</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">117</enrollment>
  <condition>Knee Osteoarthritis</condition>
  <arm_group>
    <arm_group_label>Native CT-II®</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Three capsules post-breakfast Three capsules post-dinner</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Glucosamine chondroitin</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Three capsules post-breakfast Three capsules post-dinner</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Three capsules post-breakfast Three capsules post-dinner</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Native CT -II</intervention_name>
    <description>Three capsules post-breakfast Three capsules post-dinner</description>
    <arm_group_label>Native CT-II®</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Glucosamine chondroitin</intervention_name>
    <description>Three capsules post-breakfast Three capsules post-dinner</description>
    <arm_group_label>Glucosamine chondroitin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Three capsules post-breakfast Three capsules post-dinner</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male &amp; female aged ≥ 40 to ≤ 65 years suffering from knee joint pain for at least 3
             months prior to screening.

          -  BMI ≥ 18.5 and ≤ 29.9 kg/m2.

          -  Non-vegetarians (Regardless of whether they eat chicken, fish, goat mutton, pork, beef
             or eggs).

          -  Screening Visual Analogue (VAS) scores for knee joint pain ≥ 60 on a 100-point scale.

          -  Radiographic evidence of grade II/III knee OA based on one of following criteria.

          -  Participants willing to stop the restricted supplements and medications prior to
             inclusion and throughout the study period.

          -  Participants willing to stop any home-based remedies or any other form of topical
             products intended for knee joint pain relief or any other reason for the entire study
             duration.

          -  Willing to stop the use of study designated rescue medication 48 hours prior to all
             assessment visits.

          -  Willing to abstain from food containing type II collagen only from cartilage, e.g.
             chicken, fish, beef, pork, etc. 48 hours prior to all assessment visits.

        Exclusion Criteria:

          -  Prior or ongoing medical conditions (e.g. concomitant illness, psychiatric disorders,
             etc.), abnormal medical history or physical findings.

          -  Participants with history of type II diabetes and uncontrolled hypertension.

          -  Fasting Blood glucose &gt; 125 mg/dl

          -  Systolic blood pressure ≥ 140 mmHg and/or diastolic blood pressure ≥ 90 mmHg.

          -  Radiographic evidence of Grade I or Grade IV OA based on the KL radiographic criteria
             for osteoarthritis.

          -  Any history of trauma, fractures or surgery to the index joint.

          -  Any planned surgery (diagnostic or therapeutic intervention) to the index joint during
             the participation in the study.

          -  Participants with deformity of the knee joint.

          -  Participants with a diagnosed condition which may involve or involves the index joint
             that includes but is not limited to known rheumatic or inflammatory conditions such as
             rheumatoid arthritis, osteomyelitis, osteoporosis, gout, and bone metastasis.

          -  Other pathologic lesions on X-rays of the knee.

          -  Current smokers or chronic alcoholics
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Dr. Shalini Srivastava, MD - Medicine</last_name>
    <phone>02242172325</phone>
    <email>shalini.s@vediclifesciences.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Ms.Henali Bhoir, B.Pharm</last_name>
    <phone>7738387606</phone>
    <email>crc3@vediclifesciences.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Dr. Randive's Knee &amp; Spine Clinic</name>
      <address>
        <city>Mumbai</city>
        <state>Mahararashtra</state>
        <zip>400093</zip>
        <country>India</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Dr. Ajay Randive, MS DNB Ortho</last_name>
      <phone>98199813982</phone>
      <email>drajay27@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Kurla Nursing Home</name>
      <address>
        <city>Mumbai</city>
        <state>Maharashtra</state>
        <zip>400070</zip>
        <country>India</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Dr. Asif Mulgund, MBBS DNB Ortho</last_name>
      <phone>9833346496</phone>
      <email>drasifmulgund@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Rainbow Multispeciality hospital and trauma center</name>
      <address>
        <city>Navi Mumbai</city>
        <state>Maharashtra</state>
        <zip>400708</zip>
        <country>India</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dr. Vivek Makasare, DNB ORTHO</last_name>
      <phone>9665823479</phone>
      <email>vicksm2905@yahoo.co.in</email>
    </contact>
    <investigator>
      <last_name>Dr. Vivek Makasare, DNB ORTHO</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>India</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>July 8, 2020</study_first_submitted>
  <study_first_submitted_qc>July 8, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">July 14, 2020</study_first_posted>
  <last_update_submitted>July 15, 2020</last_update_submitted>
  <last_update_submitted_qc>July 15, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 16, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoarthritis</mesh_term>
    <mesh_term>Osteoarthritis, Knee</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

